The AKT inhibitors
pipeline has more than 15 drugs. In pipeline analysis,
drugs are analyzed based on route of administration and molecule type. The pipeline
is also analyzed on the basis of monotherapy and combination therapy, and
different clinical phases including Phase III, Phase II, Phase I and Pre-clinical
stage.
Explore Report
at: https://www.psmarketresearch.com/market-analysis/akt-protein-kinase-b-inhibitors-pipeline-analysis
Phase III &
Filed
Phase III clinical trial known for the
comparison of new treatments with the standard treatment in which the safety,
efficacy and side effects of new intervention is compared with the already
existing treatment. The Phase III clinical trial takes around 2-3 years to
complete and the total number of participants vary from 100-1,000. After the
completion of Phase III stage, the company files New Drug Application (NDA) to
the regulatory authorities known as filed stage. There is no AKT inhibitor drug
in Phase III clinical trial and one drug is in filed stage. Novartis AG has
filed NDA in U.S. for midostaurin, for the treatment of FLT3-mutated acute
myeloid leukemia. The marketing authorization application has already been
accepted by the European Medicines Agency for midostaurin for the treatment of
FLT3-mutated acute myeloid leukemia.
Phase II
Rexahn Pharmaceuticals, Inc. has developed Archexin,
a phase II drug candidate for the treatment of renal cell carcinoma. Phase II
clinical trial is the second phase that answer safety, efficacy and dosing of the
new intervention. There are total 8 drugs present in phase II trial of AKT
inhibitors. Phase II clinical trial take around 2 years to complete and between
100 – 120 patients participate in the Phase II trial.
Explore Report Sample
at: https://www.psmarketresearch.com/market-analysis/akt-protein-kinase-b-inhibitors-pipeline-analysis/report-sample
Phase I
Triciribine phosphate
(PTX 200), a drug candidate of Prescient Therapeutics Ltd., is in phase I stage
of development for the treatment of acute myeloid leukemia, recurrent or
persistent platinum resistant ovarian cancer, breast cancer, lung cancer and
esophageal cancer. There are 4 drugs present in Phase I clinical stage. In Phase
I clinical trial, safety of the new intervention is determined. The trial takes
around 1-2 years to complete and the total number of volunteers participating in
the trial vary between 15 – 30.
Pipeline analysis provides description about the key companies which are
developing AKT inhibitor drugs. Some of the key players actively involved in the
research and development are AstraZeneca plc, Cellectar Biosciences Inc., GlaxoSmithKline
plc, Novartis AG, Prescient Therapeutics Ltd and Asana BioSciences, LLC.
No comments:
Post a Comment